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Eliminating caspase-7 and cathepsin B cross-
reactivity on fluorogenic caspase-3 substrates†
Martha Mackay, Ana M. Pe´rez-Lo´pez, Mark Bradley* and Annamaria Lilienkampf*
11 FRET-based fluorogenic substrates were constructed using the
pentapeptide template Asp-Glu-X2-Asp-X10, and evaluatedwith caspase-3,
caspase-7 and cathepsin B. The sequence Asp-Glu-Pro-Asp-Ser was able
to selectively quantify caspase-3 activity in vitrowithout notable caspase-7
and cathepsin B cross-reactivity, while exhibiting low lM KM values and
good catalytic eﬃciencies (7.0–16.9 lM1 min1).
Caspases (cysteine-aspartate proteases) are a family of endopeptidases
that play a key role in the controlled initiation, execution, and
regulation of apoptosis, and are essential in the development and
homeostasis of mammals.1 Their deregulation can lead to a number
of human pathologies including autoimmune diseases,2 neuro-
degenerative disorders3 and cancer.4 Caspases are produced as
procaspases and undergo post-translational activation by the
‘caspase cascade’ following apoptotic stimuli and initiation of
the extrinsic, intrinsic, or granzyme B apoptotic pathways.5
Inactivation of the apoptotic intrinsic pathway is often regarded
as a ‘hallmark of cancer’ as it leads to the uncontrolled prolif-
eration of cells.6 The intrinsic pathway responds to intercellular
stress triggers, including oncogene activation and DNA damage,
and therefore is often targeted in the treatment of cancer.7 In
addition, since caspases are usually directly involved in the early
stages of apoptosis, they are attractive targets for molecular
imaging, especially executioner caspase-3, which is down regu-
lated in a variety of cancers.8
Current methods of caspase-3 detection include the use of
antibodies9 and fluorescent inhibitors.10 In addition, FRET-
based fluorogenic substrates, consisting of either small molecule
fluorophores11 or fluorescent fusion proteins,12 have been developed,
typically applying the substrate sequence Asp-Glu-Val-Asp
(DEVD).13 Commercially available substrates, such as Ac-Asp-
Glu-Val-Asp-AFC (AFC = 7-amino-4-trifluoromethyl-coumarin)
and MCA-Asp-Glu-Val-Asp-Ala-Pro-Lys-DNP (MCA = 7-methoxy-
coumarin-4-yl)acetyl, (DNP = dinitrophenyl), have been utilised
to analyse caspase-3 activity in cell lysates; however, they are
unable to measure active caspase in intact cells for real-time
analysis due to their inability cross the cell membrane and poor
optical properties. Asp-Glu-Val-Asp-NucViewt, which displays
fluorescence upon cleavage and subsequent DNA binding, can
be used to measure caspase-3 activity in cell-based assays.14 All
the above substrates are, however, based on the recognition
sequence Asp-Glu-Val-Asp and therefore cross-react especially
with caspase-7 and cathepsin B.15 Low expression of proapoptotic
caspase-7 is also associated with many cancers, and cathepsin B is
often overexpressed in cancerous cells, highlighting the necessity to
develop substrates and probes that can detect caspase-3 activation
without cross-reactivity with these other enzymes. Recently,
caspase-3 selectivity over other caspase isoforms was achieved
by incorporation of unnatural amino acids into a pentapeptide
recognition sequences to enable imaging of caspase-3 activity in
live cells.16 Similarly, substitution of glutamic acid in Asp-Glu-
Val-Asp with pentafluorophenylalanine gave 4.5-fold selectivity
over caspase-7 in vitro along with good selectivity over isoforms
6, 8, 9 and 10.17
In this study, internally quenched fluorogenic substrates to
selectively detect caspase-3 over caspase-7 and cathepsin B were
designed and synthesised, and evaluated against human
recombinant caspase-3, caspase-7 and cathepsin B. A focused
11-member library of internally quenched substrates was
designed incorporating a pentapeptide recognition sequence
(X4–X3–X2–X1–X10). Residue X4 is where the most variability is
found within substrates of the caspase family, with preference
absolute for aspartic acid for caspase-3 and -7.18 Caspases are
not as selective for the X3 position, although glutamic acid is by
far the most favoured residue.18 Caspase-3 and -7 both prefer
hydrophobic residues at the X2 position, with caspase-7 having
far more specific requirements than caspase-3, retaining a
higher preference for valine.18a This gives rise to the possibility
of improving specificity towards caspase-3 by altering the X2
position.18a,19 Similarly, substitution of valine at the X2 position
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of Asp-Glu-Val-Asp with proline is known to abolish binding to
cathepsin B.20 The X10 position was incorporated into the
recognition sequence to explore if selectivity could be tuned
by looking at the residue next to the cleavage/recognition site.
At the X10 position, natural caspase-3 substrates typically show a
high preference for small amino acids.21 Therefore, based on
these known substrate requirements for caspase-3 and -7 and
cathepsin B, a substrate library was designed, incorporating a
FRET pair constructed using carboxyfluorescein as the donor
(lEx/Em 492/517 nm) and methyl red (2-(N,N-dimethyl-4-amino-
phenyl)azobenzenecarboxylic acid) (lmax B 480 nm) as the
acceptor/quencher (see Fig. 1). In the substrates, the X2 position
contained either valine or proline, and X10 glycine, alanine or
serine. In addition, a 6-aminohexanoic acid (Ahx) spacer was
positioned between the X10 residue and the methyl red motif in
to investigate possible steric hindrance from the quencher.
The substrates 1–11 (Fig. 1, Table 1) were synthesised on an
Fmoc-Rink-amide linker derivatised aminomethyl polystyrene
resin (1% DVB, 100–200 mesh, loading 1.2 mmol g1) using
standard Fmoc solid-phase chemistry with DIC and Oxyma as
the coupling combination (ESI,† Schemes S1 and S2). Fmoc-
Lys(Dde)-OH was coupled onto the Rink-linker followed by
coupling of the Ahx linker (when present) and next five amino
acids (Asp-Glu-X2-Asp-X10). With the amino-terminus Fmoc
group still attached, the Dde protecting group was selectively
removed with NH2OHHCl/imidazole, followed by coupling of
methyl red (in essence Fmoc-Lys(Dde)-OH is a bi-functional
spacer utilising the orthogonal nature of the Fmoc and Dde
protecting groups).22 Finally, Ahx spacer and 5(6)-carboxyfluorescein
were consecutively coupled. This modular approach allows for
the changing of the quencher or conversion of the positions of
the quencher and the fluorophore at final stages of the synthesis.
After deprotection and cleavage off the resin, the substrates were
purified by preparative RP-HPLC and analysed by MALDI-ToF MS.
Peptides 1–11 were initially evaluated for their ability to act as
substrates for caspase-3 and -7 at 2.5, 5 and 10 mM allowing the
effects of the X2 and X10 substitutions to be assessed. All the
substrates had low background fluorescence levels and showed
time dependent activation with caspase-3 (ESI,† Fig. S1). Sub-
strates 2 (Asp-Glu-Pro-Asp-Ala) and 3 (Asp-Glu-Pro-Asp-Ser), both
of which have proline at the X2 position, showed reduced
activation with caspase-3 compared to the other probes; how-
ever, this activity was restored by introduction of the Ahx spacer
(8 and 10), suggesting that the reduced cleavage of 2 and 3 arose
from steric hindrance by the methyl red moiety in combination
with the proline residue. In the preliminary screen, no signifi-
cant preference was observed for glycine, alanine or serine at the
X10 position. Substrate 9 showed a 3 and 5-fold higher increase in
fluorescence than Ac-Asp-Glu-Val-Asp-AFC (AFC) and MCA-Asp-
Glu-Val-Asp-Ala-Pro-Lys-DNP (MCA), respectively (ESI,† Fig. S2).
In the initial screens, caspase-7 showed significantly lower cleavage
of substrates containing proline at X2 position, confirming
that selectivity can be achieved by replacing valine in that position
(ESI,† Fig. S3 and S4).19c
To evaluate the eﬀectives of the substrates, as well as to
further investigate selectivity, the KM and kcat values of 1–11
were determined for caspase-3 and caspase-7 (Table 2). All
the substrates exhibited good affinity for caspase-3 (KM values
o5 mM) compared to AFC and MCA (KM values 9.8 mM and
13.5 mM, respectively). Substrates bearing a valine at X2 position
typically showed lower KM values than the corresponding
peptides bearing a X2 proline, with the exception of substrate
10 (sequence Asp-Glu-Pro-Asp-Ser- Ahx, KM 1.8 mM), which
showed the same binding as 11 (Asp-Glu-Val-Asp-Ser-Ahx, KM
1.7 mM). When the substrates were ranked by their caspase-3
catalytic efficiency (kcat/KM), more of a division between them
was observed. Peptides 2 and 8, both bearing proline at the X2
position and alanine at the X10, were poor substrates for
caspase-3 with kcat/KM values of 1.8 and 3.2 mM
1 min1,
respectively. Within the series, 6 (Asp-Glu- Pro-Asp-Gly-Ahx) and 9
(Asp-Glu-Val-Asp-Ala-Ahx) had the highest catalytic efficiency
(22.2 and 24.2 mM1 min1, respectively) proving that the enzyme
Fig. 1 Design of the internally quenched substrate library, incorporating a
pentapeptide recognition sequence Asp-Glu-X2-Asp-X10 (caspases cleave
between Asp and X10). The amino-terminus bears a 6-aminohexanoic acid
(Ahx) spacer and 5(6)-carboxyfluorescein (mixture of isomers) as the donor
fluorophore, and the carbon-terminus has a methyl red (quencher)
coupled to a lysine side chain. See Table 1 for each individual substrate
sequences.
Table 1 11-membered FRET-based substrate library FAM-Ahx-Asp-Glu-
X2-Asp-X10-spacer-Lys(MR)-NH2 (see Fig. 1 for structures)
a
Substrate X2 X10 Spacer
1 Val Gly —
2 Pro Ala —
3 Pro Ser —
4 Val — Ahxb
5 Pro — Ahx
6 Pro Gly Ahx
7 Val Gly Ahx
8 Pro Ala Ahx
9 Val Ala Ahx
10 Pro Ser Ahx
11 Val Ser Ahx
a For the solid-phase synthesis and characterisation of the fluorogenic
substrates, see ESI. b Ahx = 6-aminohexanoic acid.
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can efficiently cleave substrates with proline at the X2 position.
Based on the catalytic efficiency, the X10 position overall had a
slight preference for glycine and serine over alanine, especially
with substrates incorporating proline at X2.
With caspase-7, substratesMCA and AFC had a KM values of
15.1 and 10.8 mM. At the X10 position, caspase-7 had a clear
preference for glycine with 1 and 6 having kcat/KM values of 8.6
and 8.4 mM1 min1, respectively. Substrates 2 (Asp-Glu-Pro-
Asp-Ala) and 3 (Asp-Glu-Pro-Asp-Ser) showed negligible aﬃnity to
the enzyme (KM could not be determined). Remarkably 10, which
was eﬃciently cleaved by caspase-3 (kcat/KM 16.9 mM
1 min1), was
a poor substrate for caspase-7 (kcat/KM 0.5 mM
1 min1) further
demonstrating that the sequence Asp-Glu-Pro-Asp-Ser-(Ahx)
provides good specificity for caspase-3. Fig. 2 shows a direct
comparison of fluorescence increase of probes 3, 10 and 11
after incubation with caspase-3 and caspase-7.
To further examine the specificity of the substrates, reactivity
with cathepsin B was evaluated (ESI,† Fig. S5). The sequences
incorporating proline at the X2 position (peptides 5, 6, 8, and 10)
proved to be poor substrates for cathepsin B and were cleaved
with a much lower eﬃciency than their valine counterparts, with
5 (Asp-Glu-Pro-Asp-Ahx) showing no increase in fluorescence.
Substrates 6 and 10 showed significantly reduced cleavage by
cathepsin B. To establish the relative aﬃnity of cathepsin B and
caspase-3 for the same substrate, the cleavage rates by the two
enzymes were directly compared, with 5, 6, and 10 showing the
highest selectivity towards caspase-3 even with a 1.7-fold higher
cathepsin B concentration (Fig. 3).
Conclusions
11 FRET-based fluorogenic substrates, having a pentapeptide
sequence with two variable positions, were designed and
synthesised with the aim of identifying a caspase-3 selective
peptide. Replacement of the valine with a proline in the
traditional, non-selective Asp-Glu-Val-Asp recognition sequence
yielded substrates with good selectivity over caspase-7 and
cathepsin B. In particular peptide sequence Asp-Glu-Pro-Asp-
Ser (substrates 3 and 10), was able to selectively quantify
caspase-3 activity in vitro without notable caspase-7 and cathe-
psin B cross-reactivity. Furthermore, the binding aﬃnities of
these new substrates for caspase-3 were significantly increased
(43-fold) compared to the two widely used substratesMCA and
AFC, compared to the two commercially available fluorogenic
caspase-3 substrates, while also exhibiting good catalytic eﬃciency.
The substrates based on Asp-Glu-Pro-Asp-Ser, have the potential to
solve experimental issues caused by the lack of enzyme selectivity of
Table 2 Kinetic analysis of substrates 1–11 (n = 3) with caspase-3 and caspase-7
Caspase-3 Caspase-7
Probe KM (mM) kcat (min
1) kcat/KM (mM
1 min1) KM (mM) kcat (min
1) kcat/KM (mM
1 min1)
1 2.3  0.5 23.4  1.4 10.3 1.2  0.2 10.2  0.5 8.6
2 4.6  0.5 8.4  0.3 1.8 n/ac n/a n/a
3 2.9  0.5 20.1  1.0 7.0 n/a n/a n/a
4 1.7  0.3 13.4  0.5 7.8 2.9  0.5 10.1  0.6 3.4
5 2.7  0.4 36.5  1.7 13.3 2.4  0.5 8.2  0.5 3.5
6 2.6  0.4 58.4  2.4 22.2 2.1  0.2 17.7  0.6 8.4
7 1.4  0.2 20.4  0.8 14.9 5.1  0.9 19.9  1.3 3.9
8 3.5  0.5 11.1  0.5 3.2 27.5  8.0 3.8  0.7 0.14
9 2.2  0.3 53.3  2.4 24.2 3.4  0.3 10.7  0.3 3.2
10 1.8  0.3 30.7  1.2 16.9 5.2  0.8 2.6  0.2 0.5
11 1.7  0.3 19.7  0.9 11.7 2.7  0.4 6.4  0.3 2.4
MCAa 13.5  2.6 13.5  1.3 1.0 15.1  3.2 5.9  0.7 0.4
AFCb 9.8  1.9 14.7  1.2 1.5 10.8  2.8 11.6  1.4 1.1
a MCA = MCA-Asp-Glu-Val-Asp-Ala-Pro-Lys-DNP. b AFC = Ac-Asp-Glu-Val-Asp-AFC. c Could not be determined.
Fig. 2 Comparison of fluorescence increase (lEx/Em 485/525 nm) with
substrates 3 (Asp-Glu-Pro-Asp-Ahx), 10 (Asp-Glu-Pro-Asp-Ser-Ahx) and
11 (Asp-Glu-Val-Asp-Ser-Ahx) at 3.1 mM (n = 3, standard deviation 1.0–
3.1 RFU) incubated with caspase-3 and caspase-7 (15 nM) for 60 min.
Fig. 3 Comparison of activation by caspase-3 (15 nM) and cathepsin B (25 nM)
with substrates (10 mM, n = 3) containing proline or valine at the X2 position
(6 vs. 7 and 10 vs. 11). The fluorescencewas divided by the background
fluorescence (no enzyme) to give a ‘‘RFU fold increase’’ for each probe
((RFUenzyme/RFUblank)–1). This was done to allow comparison with the
reduced fluorescence of fluorescein in the acidic cathepsin buffer (pH 5).
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commonly used substrates, providing a more accurate analysis of
caspase-3 activity in cancer and beyond. Application of these
selective substrates to probes enabling caspase-3 imaging in
cell-based assays is currently underway.
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